Micreos BV, of Hague, the Netherlands, said it secured €30 million (US$33.6 million) in funding to accelerate the development of its endolysin technology. The proceeds will support the clinical development program of its endolysin XZ-700 and the U.S. launch of its OTC Gladskin product for eczema.